Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Hormone for Post-Concussion Symptoms
NCT05660356Phase 1Unknown
- Sponsor
- University of Calgary
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
01
Overview
Phase 1, randomised, double-blind trial in growth hormone deficiency (GHD) and Post-concussion syndrome (PCS) comparing Growth Hormone with Placebo (2 arms). Primary endpoint: Quality of Life Assessment of Growth Hormone Deficiency in Adults at 3 months. Status: unknown.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)Post-concussion syndrome (PCS)
Beyond the preview
Go deeper on NCT05660356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660356.